PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20454513-4	2010	Other studies, therefore, were performed only in SW480 cells where silibinin significantly decreased beta-catenin-dependent T-cell factor-4 (TCF-4) transcriptional activity and protein expression of beta-catenin target genes such as c-Myc and cyclin D1.	Silybin	67-76	cyclin D1	Homo sapiens	243-252	
20628792-8	2010	Silibinin also targeted signaling molecules involved in CRC proliferation and survival (cyclin D1, c-Myc and survivin) as well as angiogenesis regulators (VEGF and iNOS).	Silybin	0-9	cyclin D1	Homo sapiens	88-97	
20454513-7	2010	Analyses of xenografts showed that similar to cell culture findings, silibinin decreases proliferation and expression of beta-catenin, cyclin D1, c-Myc, and CDK8 but induces apoptosis in vivo.	Silybin	69-78	cyclin D1	Homo sapiens	135-144	
14614451-4	2003	In mechanistic studies related its effect on cell cycle progression, silibinin treatment resulted in an upregulation of Kip1/p27 and Cip1/p21 protein as well as mRNA levels, and decreased CDK2, CDK4, cyclin E and cyclin D1 protein levels together with an inhibition in CDK2 and CDK4 kinase activities.	Silybin	69-78	cyclin D1	Homo sapiens	213-222	
18339887-6	2008	Antiproliferative and proapoptotic effects of silibinin were associated with down-regulation of extracellular signal-regulated kinase 1/2 (ERK1/2) and Akt phosphorylation as well as cyclin D1 expression.	Silybin	46-55	cyclin D1	Homo sapiens	182-191	
16322307-7	2005	Mechanistic studies revealed that silibinin induces Kip1/p27 but decreases cyclin D1, cyclin D3, cyclin E, cyclin-dependent kinase (CDK)-2, and CDK4 levels in both cell lines.	Silybin	34-43	cyclin D1	Homo sapiens	75-84	
19509268-4	2009	Moreover, polysome profile analysis of silibinin-treated cells shows a decrease in polysome content and translation of cyclin D1 mRNA.	Silybin	39-48	cyclin D1	Homo sapiens	119-128	
11759294-4	2001	In terms of cell cycle regulators, silibinin treatment showed an induction of Cip1/p21 and Kip1/p27 together with a significant decrease in cyclin-dependent kinase (CDK)-4, CDK2, and cyclin D1.	Silybin	35-44	cyclin D1	Homo sapiens	183-192	
12479270-15	2002	Silibinin-treated cells showed up to 2.4- and 3.6-fold increases in Cip1/p21 and Kip1/p27 levels, respectively, and a decrease in CDK2 (80%), CDK4 (98%), and cyclin D1 (60%).	Silybin	0-9	cyclin D1	Homo sapiens	158-167	
28120452-8	2017	Further, silibinin treatment decreased the phosphorylated Akt (Serine 473), phosphorylated ERK1/2 (Threonine 202/Tyrosine 204), cyclin D1 and Gli-1 level but increased the SUFU expression in ASZ001-Sant-1-resistant cells.	Silybin	9-18	cyclin D1	Homo sapiens	128-137	
10377442-5	1999	Silibinin-induced G1 arrest was associated with a marked decrease in the kinase activity of cyclin-dependent kinases (CDKs) and associated cyclins because of a highly significant decrease in cyclin D1, CDK4, and CDK6 levels and an induction of Cip1/p21 and Kip1/p27 followed by their increased binding with CDK2.	Silybin	0-9	cyclin D1	Homo sapiens	191-200	
29920623-0	2018	Synergistic Anti-proliferative Effects of Metformin and Silibinin Combination on T47D Breast Cancer Cells via hTERT and Cyclin D1 Inhibition.	Silybin	56-65	cyclin D1	Homo sapiens	120-129	
28610415-8	2017	Conclusion: The data provideevidence that synergistic antiproliferative effects of Chrysin and Silibinin are linked to the down-regulation of cyclinD1 and hTERT genes, and suggest that their combination may have therapeutic value in treatment of breast cancer.	Silybin	95-104	cyclin D1	Homo sapiens	142-150	
25868784-5	2015	Silibinin with 0.5 or 5 microM arsenic induced G1 or G2/M phase arrest, respectively, and decreased the protein levels of CDK2, -4, and -6 and cyclin D1, D3, and E and increased CDK inhibitors p21 and p27.	Silybin	0-9	cyclin D1	Homo sapiens	143-152	
28030611-9	2016	PDGF-stimulated cell cycle in HTFs was delayed by silibinin, and the related cyclin D1 and CDK4 were also suppressed by silibinin.	Silybin	120-129	cyclin D1	Homo sapiens	77-86